Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Level 4 - case-series / case-control
Case-control proteomic biomarker discovery with validation in an independent cohort
PubMed 34438448 · doi:10.1182/bloodadvances.2020004016
What was done
Researchers performed proteomic quantification of 1,178 serum analytes in 88 patients with idiopathic multicentric Castleman disease (iMCD), 60 disease controls (20 human herpesvirus-8-associated MCD, 20 Hodgkin lymphoma, and 20 rheumatoid arthritis), and 42 healthy controls. Unsupervised clustering was applied to classify iMCD proteomes and identify siltuximab response biomarkers. A 7-analyte panel (apolipoprotein E, amphiregulin, serum amyloid P-component, inactivated complement C3b, immunoglobulin E, IL-6, erythropoietin) was tested in an independent validation cohort. Enrichment analyses and immunohistochemistry were conducted to uncover therapeutic targets for siltuximab nonresponders.
What was found
iMCD serum proteomes showed significant heterogeneity and did not cluster with overlapping disease controls. Clustering identified a novel iMCD subgroup with superior response to siltuximab, validated using the 7-analyte panel in an independent cohort. Enrichment analyses and immunohistochemistry identified Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling as a candidate target. The abstract does not provide exact numbers, response rates, or test performance metrics (such as sensitivity, specificity, or AUC).
Why it matters
Siltuximab is the only FDA-approved therapy for iMCD, but roughly two-thirds of patients do not respond and lack validated predictive tests. This panel provides a potential stratification tool, and the identification of JAK/STAT3 signaling offers a mechanistic rationale for testing JAK inhibitors in nonresponders.
Limits
The abstract does not disclose the sample size of the independent validation cohort, nor does it provide quantitative performance metrics or effect sizes. Therapeutic targeting of JAK/STAT3 signaling remains preclinical and requires evaluation in prospective clinical trials.
Cited by
- supports A refractory Castleman disease patient in Chicago who failed sirolimus responded successfully to ruxolitinib.